ivarmacitinib cream (ARQ-252) / Arcutis - LARVOL DELTA

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo (clinicaltrials.gov) - P2 | N=114 | Terminated | Sponsor: Arcutis Biotherapeutics, Inc. | Phase classification: P2a ➔ P2

Phase classification • Dermatology • Immunology • Vitiligo

A Review of Existing and New Treatments for the Management of Hand Eczema. (PubMed, J Cutan Med Surg) - "These included studies for dupilumab, ruxolitinib, delgocitinib (LEO124249), gusacitinib (ASN002), AFX 5931, and roflumilast (ARQ-252). Two major classes of drugs emerging for the treatment of hand eczema include IL-4/IL-13 inhibitors and JAK inhibitors. With the increase in efficacy seen with these new drugs, we are also noting improved adverse effect profiles, making them attractive options to add to a clinician's management toolbox for patients with hand eczema."

Journal • Review • Atopic Dermatitis • Contact Dermatitis • Dermatitis • Dermatology • Immunology • IL13 • IL4

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Ivarmacitinib (SHR0302) in Adult Patients with Moderate to Severe Alopecia Areata. (PubMed, J Am Acad Dermatol) - "Treatment with ivarmacitinib 4 mg and 8 mg doses in moderate and severe AA patients for 24 weeks was efficacious and generally tolerated."

Clinical • Journal • P2 data • Alopecia • Follicular Lymphoma • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Novel Coronavirus Disease • Oncology • Pneumonia • Respiratory Diseases • CD8 • JAK1

Topical and systemic JAK inhibitors in hand eczema - a narrative review. (PubMed, Expert Rev Clin Immunol) - "Treatment targeting specific immune pathways enables precise management and extends range of potential therapeutic options. Despite early promising results, future studies need to evaluate JAK inhibitors safety, potential risks and benefits resulting from the treatment, as well as impact of the therapy on patients QoL."

Journal • Review • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immune Modulation • Immunology • Inflammation

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo (clinicaltrials.gov) - P2a; N=114; Terminated; Sponsor: Arcutis Biotherapeutics, Inc.; N=500 ➔ 114; Trial completion date: Sep 2023 ➔ Aug 2021; Recruiting ➔ Terminated; Trial primary completion date: Aug 2023 ➔ Aug 2021; Sponsor Decision

Clinical • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Dermatology • Vitiligo

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo (clinicaltrials.gov) - P2a; N=500; Recruiting; Sponsor: Arcutis Biotherapeutics, Inc.

Clinical • New P2a trial • Dermatology • Vitiligo

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema (clinicaltrials.gov) - P1/2; N=230; Completed; Sponsor: Arcutis Biotherapeutics, Inc.; Active, not recruiting ➔ Completed; Trial completion date: Dec 2021 ➔ Feb 2021; Trial primary completion date: Dec 2021 ➔ Feb 2021

Clinical • Trial completion • Trial completion date • Trial primary completion date • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema (clinicaltrials.gov) - P1/2; N=230; Active, not recruiting; Sponsor: Arcutis Biotherapeutics, Inc.; Recruiting ➔ Active, not recruiting

Clinical • Enrollment closed • Atopic Dermatitis • Contact Dermatitis • Dermatology • Immunology

Arcutis Initiates Patient Enrollment in the Phase 2b Portion of the Phase 1/2b Study Evaluating ARQ-252 in Chronic Hand Eczema (GlobeNewswire) - "Arcutis Biotherapeutics...today announced that it initiated enrollment in the Phase 2b portion of the Phase 1/2b study of ARQ-252...in adult patients with chronic hand eczema. Topline data from this trial are expected in the second half of 2021."

Enrollment open • P1/2 data • Atopic Dermatitis • Dermatology

Safety and Efficacy of ARQ-252 Cream in Subjects With Chronic Hand Eczema (clinicaltrials.gov) - P1/2; N=221; Recruiting; Sponsor: Arcutis Biotherapeutics, Inc.

Clinical • New P1/2 trial